Fibrocell Up on FDA Designation for Gene Therapy Candidate

Fibrocell Science, Inc. FCSC announced that the FDA has granted Regenerative Medicine Advanced Therapy (“RMAT”) designation to its gene therapy candidate, FCX-007. The candidate is being developed for the treatment of recessive dystrophic epidermolysis bullosa ("RDEB"), a rare, genetic skin disorder.

The RMAT designation was created under the 21st Century Cures Act and is granted to speed up the development and review of gene therapies that target serious or life-threatening conditions. The designation also indicates that FCX-007 can be eligible for accelerated approval and priority review depending upon certain criteria. The designation is similar to Breakthrough Therapy designation granted to drugs.

The candidate already enjoys Orphan Drug, Rare Pediatric Disease and Fast Track designations in the United States.

Shares of Fibrocell rallied 10.7% on May 29 following the announcement. However, so far this year, Fibrocell’s shares have gained 25% compared with the industry’s increase of 0.8%.

 

 

Currently there are no approved treatments for RDEB. FCX-007 can be a potentially transformative treatment option for the given skin disorder if it wins approval. In March, the FDA provided guidance on the design aspects of Fibrocell’s proposed phase III study on FCX-007 named DEFI-RDEB in a Type-B meeting. The company expects to initiate the evaluation in second-quarter 2019.

We remind investors that Fibrocell is developing the candidate in collaboration with Intrexon Corporation XON under its exclusive channel collaboration. Moreover, Fibrocell collaborated with privately held Castle Creek Pharmaceuticals to develop/commercialize FCX-007. Fibrocell is eligible to receive upfront as well as milestone payments from Creek Pharmaceuticals.

Fibrocell is developing another gene therapy candidate, FCX-013, for the treatment of moderate-to-severe localized scleroderma. The company is currently enrolling in the phase I portion of a phase I/II program on FCX-013 and expects to complete the task in the third quarter of 2019.

Fibrocell Science Inc Price

 

Fibrocell Science Inc Price

Fibrocell Science Inc price | Fibrocell Science Inc Quote

Zacks Rank & Key Picks

Fibrocell currently carries a Zacks Rank #2 (Buy). A couple of other top-ranked stocks from the biotech sector include Anika Therapeutics Inc. ANIK and Axovant Sciences Ltd. AXGT, both sporting a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Anika’s earnings estimates have been revised 4.9% upward for 2019 and 9.9% for 2020 over the past 60 days. The stock has gained 13.3% so far this year.

Axovant’s loss estimates have narrowed 3.5% for 2019 and 12.2% for 2020 over the past 60 days.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Fibrocell Science Inc (FCSC) : Free Stock Analysis Report
 
Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report
 
Intrexon Corporation (XON) : Free Stock Analysis Report
 
Axovant Sciences Ltd. (AXGT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research